If I recall, they are just starting to recruit patients for the first major trial of ibrutinib in MM at Dana-Farber in Boston. I think they projected final results in 2016; obviously, the interim results could be considerably earlier.
The original cohort got PCI-32765 420 mg per day. That showed no remission but also showed no progression. Since the drug showed no remission, the price of PCYC went down last time abstracts were released. Some of these patients could have chosen to go on to higher dose levels and these patients may not have been part of the study with PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week. There is another cohort that was to get PCI-32765 840 mg per day and a final one at same dose of 840 + Dex. recruiting all cohorts but does say that testing was not started. Last update was July 15, 2013. I do know that CLL cohorts were often staggered or at least that is what I read in Brian Koffman's Blog of his treatment in Ohio.
I think that the first cohort enrollment was filled a while ago. Second and third cohorts were nearing completion of enrollment or filling, respectively. Don't know about single agent vs dual agent and don't have any idea of dose levels.